Resumen de Investigación
Analyzed using Evidence Intelligence™

Short-term glucocorticoids decrease insulin secretion in type 2 diabetes

Última actualización 15 de agosto de 2026

Key finding

The increase in AUC Glucose was significantly higher (p = 0.016) in the T2DM group.

This study examined the effects of short-term high-dose glucocorticoid exposure on beta-cell function in adults with type 2 diabetes, finding significant changes in glucose and insulin metrics.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Short-Term (≤3 mo)

Risk of bias

Some Concerns

Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

This study examined the effects of short-term high-dose glucocorticoid exposure on beta-cell function in adults with type 2 diabetes, finding significant changes in glucose and insulin metrics.

Clinical relevance

Understanding the impact of glucocorticoids on beta-cell function is crucial for managing diabetes treatment. These findings highlight the need for careful consideration of glucocorticoid use in patients with type 2 diabetes, as it may exacerbate insulin resistance and hyperglycemia.

Keep in mind

Non-randomized study design may introduce bias. Limited sample size affects generalizability. Short duration of glucocorticoid exposure may not reflect long-term effects.

Published in

Referencia de la Revista

Publication details and source links for this paper.

Monica S, May MA, Bettina T, Yannis G, Leon F, Zhiming Z. Impact of short-term high-dose glucocorticoid exposure on beta-cell function in type 2 diabetes. PLOS ONE. 2020;15(5):e0231190. doi:10.1371/journal.pone.0231190

Efectos Principales

AUC glucose increased significantly in the T2DM group (p = 0.016).

C-peptide AUC decreased significantly in the T2DM group.

Insulinogenic index decreased significantly in the T2DM group (69.2% vs 34.3%, p = 0.008).

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Prednisone 40 mg daily for 3 days and C-peptide, Change in insulinogenic index from baseline to week 12, Glucose area under the curve (AUC), and 3 more.

Primary intervention

Prednisone 40 mg daily for 3 days

Primary outcomes

  • C-peptide
  • Change in insulinogenic index from baseline to week 12
  • Glucose area under the curve (AUC)

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

6
Evidence pairs
6
Relationships
1
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 59

1

Related topics

6

Evidence pairs

316

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 6 evidence relationships
  • Includes primary outcome data
  • Linked to 1 direct semantic evidence topic

Topic contributions

Evidence topic

Contributes evidence

Agrega evidencia relacionada a tu Evidence Tracker

Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.

Evidencia principal

Tema de evidencia

Glycemic Control

matched_outcome

Core evidence

Study findings

The primary outcomes reported in this study.

C-peptide

Prednisone 40 mg daily for 3 days → C-peptide

Prednisone 40 mg daily for 3 days → C-peptide

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence Tracker

Change in insulinogenic index from baseline to week 12

Prednisone 40 mg daily for 3 days → Change in insulinogenic index from baseline to week 12

Prednisone 40 mg daily for 3 days → Change in insulinogenic index from baseline to week 12

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
25
Negative
ConsistencyScore™
unclear
Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence Tracker

Glucose area under the curve (AUC)

Prednisone 40 mg daily for 3 days → Glucose area under the curve (AUC)

Prednisone 40 mg daily for 3 days → Glucose area under the curve (AUC)

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
25
Negative
ConsistencyScore™
unclear
Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence Tracker

HOMA-B

Prednisone 40 mg daily for 3 days → HOMA-B

Prednisone 40 mg daily for 3 days → HOMA-B

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence Tracker

Insulin resistance

Prednisone 40 mg daily for 3 days → Insulin resistance

Prednisone 40 mg daily for 3 days → Insulin resistance

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence Tracker

Postprandial insulin AUC

Prednisone 40 mg daily for 3 days → Postprandial insulin AUC

Prednisone 40 mg daily for 3 days → Postprandial insulin AUC

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

evidence suggest

La Evidencia Sugiere

  • AUC glucose increased by 117.3 mmol/L/min in the T2DM group (p = 0.016).
  • C-peptide AUC decreased by 49.4 nmol/L/min.
  • Insulinogenic index decreased by 42.2% (p = 0.008).
who this applies

A quién se aplica

  • Adults diagnosed with type 2 diabetes.
  • Patients undergoing treatment that includes glucocorticoids.
keep in mind

Tener en Cuenta

  • Results may not be applicable to all populations with diabetes.
  • Further research is needed to confirm long-term effects.
  • The study's findings are based on a small sample size.
between the lines

Entre Líneas

  • Non-randomized study design may introduce bias.
  • Limited sample size affects generalizability.
  • Short duration of glucocorticoid exposure may not reflect long-term effects.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on Prednisone 40 mg daily for 3 days and C-peptide, Prednisone 40 mg daily for 3 days and Postprandial and OGTT Glucose.

Relaciones de evidencia relacionadas

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does Prednisone 40 mg daily for 3 days improve c-peptide?

Emerging Evidence

Current evidence does not show a clear benefit of Prednisone 40 mg daily for 3 days for C-peptide.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    C-peptide

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting studyUpdated: Aug 2026

Does Prednisone 40 mg daily for 3 days improve homa-b?

Emerging Evidence

Current evidence does not show a clear benefit of Prednisone 40 mg daily for 3 days for HOMA-B.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    HOMA-B

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting studyUpdated: Aug 2026

Does Prednisone 40 mg daily for 3 days improve insulin resistance?

Emerging Evidence

Current evidence does not show a clear benefit of Prednisone 40 mg daily for 3 days for Insulin resistance.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Insulin resistance

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting studyUpdated: Aug 2026

Does Prednisone 40 mg daily for 3 days improve postprandial insulin auc?

Emerging Evidence

Current evidence does not show a clear benefit of Prednisone 40 mg daily for 3 days for Postprandial insulin AUC.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Postprandial insulin AUC

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting studyUpdated: Aug 2026
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Sin anuncios. Sin rastreo.

Centrada en la evidencia, no en la publicidad.

Segura y privada

Tus datos siempre están protegidos.

Siempre al día

Se agregan nuevos estudios todos los días.